Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia

Gene

Volumn 521, Issue 2, 2013, Pages 274-281

  Soriano, Sirena ^a   Llorens, José V ^a,b   Blanco Sobero, Laura ^a   Gutiérrez, Lucía ^c   Calap Quintana, Pablo ^a   Morales, M Puerto ^c   Moltó, M Dolores ^a,d   Martínez Sebastián, M José ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^c INSTITUTO DE CIENCIA DE MATERIALES DE MADRID   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Aconitase; Climbing capability; Frataxin; Life span; Mitochondria; Oxidative stress

Indexed keywords

ACONITATE HYDRATASE; DEFERIPRONE; FERRIC ION; FRATAXIN; IDEBENONE; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CLIMBING; CONTROLLED STUDY; DROSOPHILA; ENZYME ACTIVITY; FRIEDREICH ATAXIA; HYPEROXIA; IRON CHELATION; IRON OVERLOAD; LIFESPAN; MITOCHONDRION; MOTOR COORDINATION; MOTOR PERFORMANCE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; SURVIVAL;

ACONITATE HYDRATASE; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DROSOPHILA; FRIEDREICH ATAXIA; HYPEROXIA; IRON; IRON-BINDING PROTEINS; MITOCHONDRIA; MUTATION; OXIDATIVE STRESS; PHENOTYPE; PYRIDONES; UBIQUINONE;

EID: 84876975929     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.02.049     Document Type: Article

References (53)

1. Al-Mahdawi S., et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 2006, 88:580-590.
2. Al-Mahdawi S., et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet. 2008, 17:735-746.
3. Armstrong J.S., Khdour O., Hecht S.M. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J. 2010, 24:2152-2163.
4. Artuch R., et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002, 33:190-193.
5. Babcock M., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997, 276:1709-1712.
6. Boddaert N., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
7. Botella J.A., et al. The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration. Curr. Biol. 2004, 14:782-786.
8. Bradley J.L., Blake J.C., Chamberlain S., Thomas P.K., Cooper J.M., Schapira A.H. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 2000, 9:275-282.
9. Campuzano V., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
10. Cohen A.R. New advances in iron chelation therapy. Hematology Am. Soc. Hematol. Educ. Program 2006, 42-47.
11. Cossée M., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 2000, 9:1219-1226.
12. Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 2011, 118:301-314.
13. Das N., Levine R.L., Orr W.C., Sohal R.S. Selectivity of protein oxidative damage during aging in Drosophila melanogaster. Biochem. J. 2001, 360:209-216.
14. Delaval E., Perichon M., Friguet B. Age-related impairment of mitochondrial matrix aconitase and ATP-stimulated protease in rat liver and heart. Eur. J. Biochem. 2004, 271:4559-4564.
15. Di Prospero N.A., Baker A., Jeffries N., Fischbeck K.H. Neurological effects of high dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007, 6:878-886.
16. Emond M., Lepage G., Vanasse M., Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 2000, 55:1752-1753.
17. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 1999, 456:281-284.
18. Foury F., Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997, 411:373-377.
19. Garcia-Lopez A., Monferrer L., Garcia-Alcover I., Vicente-Crespo M., Alvarez-Abril M.C., Artero R.D. Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS One 2008, 3:e1595.
20. García-López A., Llamusí B., Orzáez M., Pérez-Payá E., Artero R.D. In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11866-11871.
21. Goncalves S., Paupe V., Dassa E.P., Rustin P. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol. 2008, 8:20.
22. González-Cabo P., Llorens J.V., Palau F., Moltó M.D. Friedreich ataxia: an update on animal models, frataxin function and therapies. Adv. Exp. Med. Biol. 2009, 652:247-261.
23. Harding A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981, 104:589-620.
24. Harding A.E. Clinical features and classification of inherited ataxias. Adv. Neurol. 1993, 61:1-14.
25. Haugen A.C., et al. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. PLoS Genet. 2010, 6:e1000812.
26. Hirth F. Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol. Disord. Drug Targets 2010, 9:504-523.
27. Kakhlon O., et al. Cell functions impaired by frataxin deficiency are restored by drug mediated iron relocation. Blood 2008, 112:5219-5227.
28. Kirby K., Hu J., Hilliker A.J., Phillips J.P. RNA interference-mediated silencing of Sod2 in Drosophila leads to early adult-onset mortality and elevated endogenous oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16162-16167.
29. Koutnikova H., Campuzano V., Foury F., Dollé P., Cazzalini O., Koenig M. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 1997, 16:345-351.
30. Lagedrost S.J., et al. Idebenone in Friedreich ataxia cardiomyopathy results from a 6-month phase III study (IONIA). Am. Heart J. 2011, 161. (639-645.e1).
31. Lamarche J.B., CÔté M., Lemieux B. The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can. J. Neurol. Sci. 1980, 7:389-396.
32. Li K., Besse E.K., Ha D., Kovtunovych G., Rouault T.A. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet. 2008, 17:2265-2273.
33. Llorens J.V., et al. Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. FASEB J. 2007, 21:333-344.
34. Lynch D.R., Perlman S.L., Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 2010, 67:941-947.
35. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003, 60:1676-1679.
36. Meier T., Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J. Neurol. 2009, 256(Suppl. 1):25-30.
37. Meier T., Perlman S.L., Rummey C., Coppard N.J., Lynch D.R. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6month controlled study followed by a 12-month open-label extension study. J. Neurol. 2012, 259:284-291.
38. Monrós E., et al. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am. J. Hum. Genet. 1997, 61:101-110.
39. Pandey U.B., Nichols C.D. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 2011, 63:411-436.
40. Pandolfo M. Friedreich ataxia: the clinical picture. J. Neurol. 2009, 256(Suppl. 1):3-8.
41. Paupe V., et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 2009, 4:e4253.
42. Pineda M., et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur. J. Paediatr. Neurol. 2008, 12:470-475.
43. Puccio H., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001, 27:181-186.
44. Ribaï P., et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch. Neurol. 2007, 64:558-564.
45. Rötig A., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 1997, 17:215-217.
46. Sanchez-Casis G., Cote M., Barbeau A. Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can. J. Neurol. Sci. 1976, 3:349-354.
47. Schmucker S., Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum. Mol. Genet. 2010, 19:R103-R110.
48. Schulz J.B., et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol. 2009, 5:222-234.
49. Sohn Y.-S., Breuer W., Munnich A., Cabantchik Z.I. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008, 111:1690-1699.
50. Sturm B., et al. Friedreich's ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity?. J. Biol. Chem. 2005, 280:6701-6708.
51. Velasco-Sánchez D., et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
52. Voncken M., Ioannou P., Delatycki M.B. Friedreich ataxia-update on pathogenesis and possible therapies. Neurogenetics 2004, 5:1-8.
53. Waldvogel D., van Gelderen P., Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol. 1999, 46:123-125.